Drugs under FDA review in October include weight-loss drugs from Arena Pharmaceuticals(ARNA) and Vivus(VVUS), a diabetes drug from Amylin Pharmaceuticals(AMLN) and partners, a drug to treat opioid addiction from Alkermes(ALKS) and a treatment for fibromyalgia from Jazz Pharmaceuticals(JAZZ).
“Over two-thirds of adults in the United States are overweight or obese, and over one-third are obese” according to data from the National Health and Nutrition Examination Survey. (NHANES) 2003–2006 and 2007–2008.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.